Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Noam Stadlan

Neurological Surgery Skokie, IL Medical Doctor

NPI 1962478271 CMS profile 88530

9650 Gross Point Rd Ste 2900, Skokie, IL 60076

Open in the dashboard

General payments

$469

10 records reported · program years 2019–2025

Research payments

$3,960

Paid to them · 1 record reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$78,962 paid to institutions, not to them · program years 2019–2021

Through program year 2025, Noam Stadlan of Skokie, IL is reported in the CMS Open Payments database as having received $469 across 10 general payments and $3,960 in research payments paid to them. Separately, studies naming them as principal investigator received $78,962 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 56th percentile of Neurological Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $189 4
2025 Research $3,960 1
2024 General $14 1
2023 General $111 1
2022 General $68 1
2019 General $86 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Noam Stadlan
  • Neurological Surgery median
  • Middle half of Neurological Surgery
  • National median

In program year 2025, general payments to Noam Stadlan were reported at $189. Among 5,467 Neurological Surgery profiles paid that year, the median was $596 and the middle half received between $159 and $3,102.

Show as a table
Year Noam Stadlan Neurological Surgery median Middle half National median
2019 $86 $582 $138–$3,006 $163
2020 $0 $294 $76–$2,174 $114
2021 $0 $387 $105–$2,432 $132
2022 $68 $542 $139–$2,989 $149
2023 $111 $534 $145–$2,697 $160
2024 $14 $574 $155–$3,046 $164
2025 $189 $596 $159–$3,102 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Providence Medical Technology, Inc. $117 1 payment
  2. Medacta USA, Inc. $111 1 payment
  3. Medtronic USA, Inc. $86 3 payments
  4. Medtronic, Inc. $68 1 payment
  5. Globus Medical, Inc. $59 1 payment
  6. Orthofix Medical, Inc. $28 3 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $469 10 payments
Products named General payments · program years 2019–2025
  1. MYSPINE $111 1 payment
  2. MazorX - Renaissance $86 3 payments
  3. POWEREASE INSTRUMENTS $68 1 payment
  4. Simplify Cervical Artificial Disc $59 1 payment
  5. STIM on Track $14 1 payment
  6. Spinal-Stim $14 2 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Intrinsic Therapeutics $3,960 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 13 drugs

Part D claims

933

Median for Neurosurgery: 83

Drug cost

$8,381

Median for Neurosurgery: $872

Branded share of claims

4.2%

Median for Neurosurgery: 16.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gabapentin Generic 287 $3,625
Diclofenac Sodium Generic 140 $976
Tizanidine Hcl Generic 111 $901
Duloxetine Hcl Generic 45 $746
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 39 $548
Meloxicam Generic 132 $441
Methylprednisolone Generic 51 $269
Baclofen Generic 25 $218
Amitriptyline Hcl Generic 24 $217
Pregabalin Generic 14 $163

The 10 drugs with the highest cost, of 13 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,779 Part D prescribers listed as Neurosurgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 66 billing codes

Paid by Medicare

$412,301

Medicare's payments for the services billed

Medicare patients

523

Average age 76

Services billed

1,615

311 women, 212 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 73%
Diabetes 29%
Osteoporosis 29%
Ischemic heart disease 28%
Depression 25%
Chronic kidney disease 23%
Atrial fibrillation 17%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

11 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurological Surgery in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record